Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals' Net Cash Flow history runs 14 years deep, the most recent figure standing at $900000.0 for Q1 2026.

• In Q1 2026, Net Cash Flow fell 97.1% year-over-year to $900000.0; the TTM figure through Mar 2026 stood at -$11.8 million (up 35.85% YoY), while the FY2025 annual figure was $18.4 million, up 144.68% from the prior year.
• Net Cash Flow was $900000.0 for Q1 2026 at Amphastar Pharmaceuticals, up from -$46.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $119.8 million in Q3 2023 to a low of -$126.3 million in Q4 2023.
• Historically, Net Cash Flow has averaged $2.7 million across 5 years, with a median of $900000.0 in 2026.
• Biggest YoY gain for Net Cash Flow was 1459.14% in 2023; the steepest drop was 10738.45% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$1.2 million in 2022, then slumped by 10738.45% to -$126.3 million in 2023, then jumped by 67.93% to -$40.5 million in 2024, then declined by 13.79% to -$46.1 million in 2025, then jumped by 101.95% to $900000.0 in 2026.
• The last three Net Cash Flow figures came in at $900000.0 (Q1 2026), -$46.1 million (Q4 2025), and $28.6 million (Q3 2025), per Business Quant data.